142 related articles for article (PubMed ID: 20099981)
1. The radiosensitising effect of olomoucine derived synthetic cyclin-dependent kinase inhibitors.
Korinkova G; Cwiertka K; Paprskarova M; Dzubak P; Hajduch M
Neoplasma; 2010; 57(2):161-9. PubMed ID: 20099981
[TBL] [Abstract][Full Text] [Related]
2. The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics.
Schutte B; Nieland L; van Engeland M; Henfling ME; Meijer L; Ramaekers FC
Exp Cell Res; 1997 Oct; 236(1):4-15. PubMed ID: 9344580
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
[TBL] [Abstract][Full Text] [Related]
4. Cyclin-dependent kinase inhibitors block proliferation of human gastric cancer cells.
Iseki H; Ko TC; Xue XY; Seapan A; Hellmich MR; Townsend CM
Surgery; 1997 Aug; 122(2):187-94; discussion 194-5. PubMed ID: 9288122
[TBL] [Abstract][Full Text] [Related]
5. Adenovirus-mediated E2F-1 gene transfer induces an apoptotic response in human gastric carcinoma cells that is enhanced by cyclin dependent kinase inhibitors.
Atienza C; Elliott MJ; Dong YB; Yang HL; Stilwell A; Liu TJ; McMasters KM
Int J Mol Med; 2000 Jul; 6(1):55-63. PubMed ID: 10851267
[TBL] [Abstract][Full Text] [Related]
6. A novel strategy for inhibiting growth of human pancreatic cancer cells by blocking cyclin-dependent kinase activity.
Iseki H; Ko TC; Xue XY; Seapan A; Townsend CM
J Gastrointest Surg; 1998; 2(1):36-43. PubMed ID: 9841966
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.
Raynaud FI; Whittaker SR; Fischer PM; McClue S; Walton MI; Barrie SE; Garrett MD; Rogers P; Clarke SJ; Kelland LR; Valenti M; Brunton L; Eccles S; Lane DP; Workman P
Clin Cancer Res; 2005 Jul; 11(13):4875-87. PubMed ID: 16000586
[TBL] [Abstract][Full Text] [Related]
8. The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity.
Alessi F; Quarta S; Savio M; Riva F; Rossi L; Stivala LA; Scovassi AI; Meijer L; Prosperi E
Exp Cell Res; 1998 Nov; 245(1):8-18. PubMed ID: 9828096
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of radiation response by roscovitine in human breast carcinoma in vitro and in vivo.
Maggiorella L; Deutsch E; Frascogna V; Chavaudra N; Jeanson L; Milliat F; Eschwege F; Bourhis J
Cancer Res; 2003 May; 63(10):2513-7. PubMed ID: 12750274
[TBL] [Abstract][Full Text] [Related]
10. Cell cycle arrest induced in human breast cancer cells by cyclin-dependent kinase inhibitors: a comparison of the effects exerted by roscovitine and olomoucine.
Wesierska-Gadek J; Gueorguieva M; Wojciechowski J; Horky M
Pol J Pharmacol; 2004; 56(5):635-41. PubMed ID: 15591654
[TBL] [Abstract][Full Text] [Related]
11. Cyclin-dependent kinase inhibitor roscovitine induces cell cycle arrest and apoptosis in rabbit retinal pigment epithelial cells.
Wu PC; Tai MH; Hu DN; Lai CH; Chen YH; Wu YC; Tsai CL; Shin SJ; Kuo HK
J Ocul Pharmacol Ther; 2008 Feb; 24(1):25-33. PubMed ID: 18370874
[TBL] [Abstract][Full Text] [Related]
12. Meiotic inhibition with different cyclin-dependent kinase inhibitors in bovine oocytes and its effects on maturation and embryo development.
Adona PR; Lima Verde Leal C
Zygote; 2004 Aug; 12(3):197-204. PubMed ID: 15521709
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of post-transcriptional RNA processing by CDK inhibitors and its implication in anti-viral therapy.
Holcakova J; Muller P; Tomasec P; Hrstka R; Nekulova M; Krystof V; Strnad M; Wilkinson GW; Vojtesek B
PLoS One; 2014; 9(2):e89228. PubMed ID: 24586613
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and in vitro evaluation of novel 2,6,9-trisubstituted purines acting as cyclin-dependent kinase inhibitors.
Legraverend M; Ludwig O; Bisagni E; Leclerc S; Meijer L; Giocanti N; Sadri R; Favaudon V
Bioorg Med Chem; 1999 Jul; 7(7):1281-93. PubMed ID: 10465404
[TBL] [Abstract][Full Text] [Related]
15. Cellular phototoxicity evoked through the inhibition of human ABC transporter ABCG2 by cyclin-dependent kinase inhibitors in vitro.
An R; Hagiya Y; Tamura A; Li S; Saito H; Tokushima D; Ishikawa T
Pharm Res; 2009 Feb; 26(2):449-58. PubMed ID: 18841444
[TBL] [Abstract][Full Text] [Related]
16. The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway.
Whittaker SR; Walton MI; Garrett MD; Workman P
Cancer Res; 2004 Jan; 64(1):262-72. PubMed ID: 14729633
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of 6-DMAP, olomoucine and roscovitine on Xenopus oocytes and eggs.
Flament S; Bodart JF; Bertout M; Browaeys E; Rousseau A; Vilain JP
Zygote; 2000 Feb; 8(1):3-14. PubMed ID: 10840869
[TBL] [Abstract][Full Text] [Related]
18. Roscovitine modulates DNA repair and senescence: implications for combination chemotherapy.
Crescenzi E; Palumbo G; Brady HJ
Clin Cancer Res; 2005 Nov; 11(22):8158-71. PubMed ID: 16299248
[TBL] [Abstract][Full Text] [Related]
19. The expression of retinoblastoma and Sp1 is increased by low concentrations of cyclin-dependent kinase inhibitors.
Peñuelas S; Alemany C; Noé V; Ciudad CJ
Eur J Biochem; 2003 Dec; 270(24):4809-22. PubMed ID: 14653808
[TBL] [Abstract][Full Text] [Related]
20. Proteomics approach in classifying the biochemical basis of the anticancer activity of the new olomoucine-derived synthetic cyclin-dependent kinase inhibitor, bohemine.
Kovárová H; Hajdúch M; Korínková G; Halada P; Krupicková S; Gouldsworthy A; Zhelev N; Strnad M
Electrophoresis; 2000 Nov; 21(17):3757-64. PubMed ID: 11271495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]